Background & Aims In individuals with compensated advanced chronic liver disease
(cACLD), the severity of portal hypertension (PH) determines the risk of decompensation …

Methods Non-invasive risk factors of CSPH were identified via systematic review and meta-
analysis of studies involving patients with hepatic venous pressure gradient (HVPG). A new …

Clinically significant portal hypertension (CSPH), defined as hepatic venous pressure
gradient (HVPG)≥ 10 mm Hg, identifies patients with compensated cirrhosis at a high risk of …

Background and Aims The hepatic venous pressure gradient (HVPG) is the standard for
estimating portal pressure but requires expertise for interpretation. We hypothesized that …

The hepatic venous pressure gradient (HVPG) is the gold standard for cirrhotic portal
hypertension (PHT), but it is invasive and specialized. Alternative non-invasive techniques …

Objective Clinical evidence suggests that the risk stratification of portal hypertension (PH)
plays a vital role in disease progression and patient outcomes. However, the gold standard …

In patients with compensated advanced chronic liver disease (cACLD), the presence of
clinically significant portal hypertension (CSPH) and varices needing treatment (VNT) bears …

Background & Aims Noninvasive and accurate methods are needed to identify patients with
clinically significant portal hypertension (CSPH). We investigated the ability of deep …

Introduction Portal hypertension (PH) drives the progression of liver cirrhosis to
decompensation and death. Hepatic venous pressure gradient (HVPG) measurement is the …

Portal hypertension is the main prognostic factor in cirrhosis. The recent emergence of
potent antiviral drugs and new algorithm of treatment for the management of complications …